Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
15 - Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
Published online by Cambridge University Press: 05 March 2016
Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Managing Myeloproliferative NeoplasmsA Case-Based Approach, pp. 129 - 136Publisher: Cambridge University PressPrint publication year: 2016
References
Swerdlow, SH, Campo, E, Harris, NL, Jaffe, ES, Pileri, SA, Stein, H, Thiele, Jl, Vardiman, JW (eds.) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008.Google Scholar
Shepherd, PC, Ganesan, TS, Galton, DA. Haematological classification of the chronic myeloid leukaemias. Baillieres Clin Haematol. 1987;1(4):887–906.CrossRefGoogle ScholarPubMed
Breccia, M, Mandelli, F, Petti, MC, D’Andrea, M, Pescarmona, E, Pileri, SA, et al. Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution. Leuk Res. 2004;28(11):1165–9.CrossRefGoogle ScholarPubMed
Martiat, P, Michaux, JL, Rodhain, J. Philadelphia-negative (Ph–) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. The Groupe Francais de Cytogenetique Hematologique. Blood. 1991;78(1):205–11.CrossRefGoogle Scholar
Hernandez, JM, del Canizo, MC, Cuneo, A, Garcia, JL, Gutierrez, NC, Gonzalez, M, et al. Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol. 2000;11(4):441–4.CrossRefGoogle ScholarPubMed
Yanagisawa, K, Ohminami, H, Sato, M, Takada, K, Hasegawa, H, Yasukawa, M, et al. Neoplastic involvement of granulocytic lineage, not granulocytic–monocytic, monocytic, or erythrocytic lineage, in a patient with chronic neutrophilic leukemia. Am J Hematol. 1998;57(3):221–4.3.0.CO;2-X>CrossRefGoogle Scholar
Bennett, JM, Catovsky, D, Daniel, MT, Flandrin, G, Galton, DA, Gralnick, H, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French–American–British Cooperative Leukaemia Group. Br J Haematol. 1994;87(4):746–54.CrossRefGoogle ScholarPubMed
Kurzrock, R, Bueso-Ramos, CE, Kantarjian, H, Freireich, E, Tucker, SL, Siciliano, M, et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol. 2001;19(11):2915–26.CrossRefGoogle ScholarPubMed
Breccia, M, Biondo, F, Latagliata, R, Carmosino, I, Mandelli, F, Alimena, G. Identification of risk factors in atypical chronic myeloid leukemia. Haematologica. 2006;91(11):1566–8.Google ScholarPubMed
Haferlach, T, Bacher, U, Kern, W, Schnittger, S, Haferlach, C. The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. Ann Hematol. 2008;87(1):1–10.CrossRefGoogle ScholarPubMed
Bohm, J, Schaefer, HE. Chronic neutrophilic leukaemia: 14 new cases of an uncommon myeloproliferative disease. J Clin Pathol. 2002;55(11):862–4.CrossRefGoogle ScholarPubMed
You, W, Weisbrot, IM. Chronic neutrophilic leukemia. Report of two cases and review of the literature. Am J Clin Pathol. 1979;72(2):233–42.CrossRefGoogle ScholarPubMed
Elliott, MA, Hanson, CA, Dewald, GW, Smoley, SA, Lasho, TL, Tefferi, A. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia. 2005;19(2):313–7.CrossRefGoogle Scholar
Pane, F, Frigeri, F, Sindona, M, Luciano, L, Ferrara, F, Cimino, R, et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood. 1996;88(7):2410–14.CrossRefGoogle ScholarPubMed
Bennour, A, Bellaaj, H, Ben Youssef, Y, Elloumi, M, Khelif, A, Saad, A, et al. Molecular cytogenetic characterization of Philadelphia-negative rearrangements in chronic myeloid leukemia patients. J Cancer Res Clin Oncol. 2011;137(9):1329–36.CrossRefGoogle ScholarPubMed
Maxson, JE, Gotlib, J, Pollyea, DA, Fleischman, AG, Agarwal, A, Eide, CA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368(19):1781–90.CrossRefGoogle ScholarPubMed
Beekman, R, Valkhof, MG, Sanders, MA, van Strien, PM, Haanstra, JR, Broeders, L, et al. Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. Blood. 2012;119(22):5071–7.CrossRefGoogle ScholarPubMed
Pardanani, A, Lasho, TL, Laborde, RR, Elliott, M, Hanson, CA, Knudson, RA, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia. 2013;27(9):1870–3.CrossRefGoogle ScholarPubMed
Fleischman, AG, Maxson, JE, Luty, SB, Agarwal, A, Royer, LR, Abel, ML, et al. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood. 2013;122(22):3628–31.CrossRefGoogle ScholarPubMed
Minakuchi, M, Kakazu, N, Gorrin-Rivas, MJ, Abe, T, Copeland, TD, Ueda, K, et al. Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET. Eur J Biochem. 2001;268(5):1340–51.CrossRefGoogle Scholar
Cristobal, I, Blanco, FJ, Garcia-Orti, L, Marcotegui, N, Vicente, C, Rifon, J, et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood. 2010;115(3):615–25.CrossRefGoogle ScholarPubMed
Piazza, R, Valletta, S, Winkelmann, N, Redaelli, S, Spinelli, R, Pirola, A, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. 2013;45(1):18–24.CrossRefGoogle ScholarPubMed
Gotlib, J, Maxson, JE, George, TI, Tyner, JW. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood. 2013;122(10):1707–11.CrossRefGoogle ScholarPubMed
Lasho, TL, Mims, A, Elliott, MA, Finke, C, Pardanani, A, Tefferi, A. Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib. Leukemia. 2014;28(6):1363–5.CrossRefGoogle ScholarPubMed
Zittoun, R, Rea, D, Ngoc, LH, Ramond, S. Chronic neutrophilic leukemia. A study of four cases. Ann Hematol. 1994;68(2):55–60.CrossRefGoogle ScholarPubMed
Koldehoff, M, Beelen, DW, Trenschel, R, Steckel, NK, Peceny, R, Ditschkowski, M, et al. Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia. Bone Marrow Transplant. 2004;34(12):1047–50.CrossRefGoogle ScholarPubMed
Tefferi, A, Thiele, J, Vannucchi, AM, Barbui, T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014;28(7):1407-13.CrossRefGoogle Scholar
- 1
- Cited by